• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Thrice weekly iron supplementation non-inferior to thrice-daily treatment for iron-deficiency anemia

byAlex Chan
June 8, 2023
in Chronic Disease, Hematology
Reading Time: 2 mins read
2 Minute Medicine Rewind July 29, 2019
Share on FacebookShare on TwitterShare on LinkedIn

1. This noninferiority trial found that at 12 weeks, hematologic responses to 200 mg ferrous fumarate thrice weekly (TIW) were not significantly different than the TID iron treatment group for iron deficiency anemia (IDA) by week 12 of treatment. 

Evidence Rating Level: 1 (Excellent)

IDA is a relatively common condition affecting patients’ quality of life. If non-inferior, a TIW treatment regimen would be more cost-effective, reduce pill burdens, and could potentially lend to a lower incidence of adverse events associated with ferrous fumarate use (e.g., metallic taste, epigastric discomfort, constipation, nausea). Therefore, this noninferiority trial sought to evaluate the effectiveness of lower dose regimens on IDA. A total of 64 patients were randomized either to the TID (n = 32) or TIW arms (n = 32) at enrollment, and by week 12, there remained 27 and 26 participants in each arm, respectively. At week 4, the hemoglobin (Hb) level in the TID arm was significantly higher than the TIW arm (9.9 vs. 10.8 g/dL, respectively, p = 0.040), but by week 12, there was no longer a significant difference between either arm (11.9 vs. 12.4 g/dL, p = 0.188). While the TID group may have seen a faster result, the difference was short-lasting. The primary endpoint of an increase in Hb of ≥ 3 g/dL was achieved by both groups without a significant difference (p > 0.05). In terms of secondary outcomes, although the mean Hb in the TID group (12.4 g/dL) was higher than in the TIW group (11.9 g/dL) by week 12, the mean Hb was not significantly different between the groups (< 0.9 g/dL). All participants from both arms recovered from anemic symptoms (fatigue, dyspnea on exertion, dizziness, sore tongue, taste disturbance, and pica) by week 12 as well. From a hematological standpoint, the transferrin saturations and serum ferritin levels between both groups were no different by week 12 (64.3% vs. 73.1%, p = 0.430). Compliance by week 12 was 95.4% in the TIW arm, and 92.0% in the TID arms. There was a relatively high attrition rate (17%) with only 64 participants to begin with, which may be interpreted as a potential limitation of this study. However, results are promising and should be further elucidated as the potential for less frequent dosing with ferrous fumarate may provide a cost-effective solution that decreases the frequency of common adverse effects associated with the supplement.

Click to read the study in Annals of Hematology

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Borderline-low hemoglobin levels linked to increased mortality

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

Tags: anemiahematologyiron deficiency anemiairon supplementation
Previous Post

Best endovascular treatment superior to vein bypass for patients with chronic limb ischemia requiring infrapopliteal revascularization

Next Post

Type 1 diabetes associated with higher brain ages and poorer cognitive performance

RelatedReports

An illustration featuring blood cells and a vial with pills, representing hemophilia and potential treatments for blood coagulation.
Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Combined lenalidomide and rituximab dose escalation found to be safe for CLL
All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026
Drug comparison trials collage: a brass balance scale with white tablets on one pan and gray capsules on the other
Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Next Post

Type 1 diabetes associated with higher brain ages and poorer cognitive performance

Ketogenic diet therapy may improve sleep symptoms in migraine patients

#VisualAbstract: Peresolimab reduces disease severity in adults with rheumatoid arthritis

#VisualAbstract: Peresolimab reduces disease severity in adults with rheumatoid arthritis

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.